Overview
- Trump signed the order Saturday in the Oval Office and pledged $50 million for ibogaine research alongside HHS, FDA officials, veterans and podcaster Joe Rogan.
- The directive tells the FDA to use National Priority Vouchers to accelerate reviews, with officials saying decisions could come as soon as this summer.
- Agencies will coordinate VA studies and data sharing and will open a path to the first U.S. human trials of ibogaine.
- Ibogaine remains a Schedule I, unapproved drug with known heart risks and reported deaths, and researchers warn that only rigorous, controlled trials can show if it is safe and effective.
- Veterans have sought treatment abroad based on small, non‑randomized reports of symptom relief, and Texas has already committed $50 million to ibogaine studies that could feed into federal reviews.